Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Arctic Bioscience Investor Presentation 2022

Jan 7, 2022

3536_rns_2022-01-07_f4a6642c-9619-48bc-8cbb-b5f0b07c9613.html

Investor Presentation

Open in viewer

Opens in your device viewer

Arctic Bioscience to Present at H.C. Wainwright Bioconnect Conference

Arctic Bioscience to Present at H.C. Wainwright Bioconnect Conference

Arctic Bioscience, a biotech company developing and commercializing

nutraceutical and pharmaceutical products based on the unique properties of

bioactive marine compounds, will present at the US investment bank H.C.

Wainwright's Bioconnect Virtual Conference - discussing the company's phase IIb

clinical trial, 2021 accomplishments, long term-strategy and 2022 priorities.

H.C. Wainwright Bioconnect Conference Details:

Date: January 10[th] from 13.00 CEST

Link: Arctic Bioscience company

presentation (https://journey.ct.events/view/54abbf16-742c-48ce-b3d1

-9eefd5c5a99c)

Full event details: H.C. Wainwright Bioconnect

Conference (https://hcwevents.com/bioconnect/)

A recording of the presentation will be available on the company's

website (https://arctic-bioscience.com/investors/reports-presentations/) from

Monday January 10[th] at 13.30 CEST.

For further information, please contact:

Danielle Glenn

CFO of Arctic Bioscience AS

Phone: +47 909 98 201

Email: [email protected]

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

nutraceutical products based on herring roe oil. Herring roe oil contains lipids

that are essential to maintain cell membranes, contributing to normal

functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience

are sold globally as bulk ingredients to other companies making dietary

supplements, and as finished goods under the Romega brand. The strategy is to

switch sales from bulk to finished goods and focus markets are USA and China.

The company is developing HRO350 - a novel investigational drug candidate with

herring roe as raw material. HRO350 is being developed for treatment of mild-to

-moderate psoriasis. This is a large patient group in need of new effective

medicines with beneficial safety profile. Arctic Bioscience is led by a team of

highly competent people with experience in developing marine oils and experience

from global pharmaceutical companies.